At CSI, we are leading the way to help successfully treat arterial calcium by creating devices designed to restore blood flow and reduce calcium.
Collaborating with leading experts to develop solutions to treat patients with advanced PAD and CAD.
When you or a loved one is diagnosed with advanced CAD or PAD and include blockages made of calcium, you're looking for solutions. CSI is committed to getting people back to what matters.
PAD is a potentially life-threatening disease where plaque, like calcium, builds up along blood vessel walls, narrowing the arteries and reducing blood flow to the legs and feet.
Often referred to as blocked arteries, CAD is the most common heart disease and can cause shortness of breath, chest pain or a heart attack.
Use our locator to find a doctor who is experienced using Cardiovascular Systems, Inc.'s (CSI) device to treat appropriate patients with PAD or CAD.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating coronary and peripheral artery disease.
Review SEC Filings, Financial Reports and Proxy Information.
View our latest news, including financial announcements, clinical research results and product approvals and launches.
Find information for investor presentations & earnings conference calls.
Review current stock price, stock chart and analyst coverage.
-0.46 ( -1.94% )
We are devoted to developing innovative solutions for treating peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD and help patients get back to what matters.
Find out more about CSI, our company history, our solutions and the ways you can join in our efforts.
The ability to serve the cardiovascular market with state-of-the-art medical technology begins with leaders.
Learn more about what it's like to work at CSI, view open positions and apply.
View our media kit and press releases, including financial announcements and clinical research results.
Review our governance documents, principles of corporate governance and code of ethics and business conduct.
Read about our company policies, monitoring, public disclosures and other details.
For more information about product availability globally, please click below.
OrbusNeich Medical Co. Ltd.:
→EMEA (Europe, Middle East, Africa)
ON has exclusive distribution rights in the following countries: Czech Republic, Slovakia, Egypt, Hong Kong, Italy, Kingdom of Saudi Arabia, Kuwait, Malaysia, Singapore, Spain, Switzerland, and United Arab Emirates; ON has non-exclusive distribution rights in Austria, France, Germany, and the Netherlands.
Medikit Co., Ltd:
In November 2016, Cardiovascular Systems, Inc. (CSI) announced that Medikit, Co., Ltd. signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Japan.
PT. Revass Utama Medika:
In February 2021, Cardiovascular Systems, Inc. (CSI) announced that PT. Revass Utama Medika signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Indonesia.
Bio-Excel (Australia) Pty. Ltd.:
In March 2021, Cardiovascular Systems, Inc. (CSI) announced that Bio-Excel Co. Ltd. signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Australia.
RSK Medical Inc.
In April 2021, Cardiovascular Systems, Inc. (CSI) announced that RSK Medical Inc. signed an exclusive sales agent agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Canada.
At CSI, weare a culture of innovation.
We observe carefully, listen closely and collaborate extensively,
seeking opportunities to help interventionalists do their jobs more easily and more effectively –
all with the goal of improving patient care.